1876 article may point to cheap diabetes drug

26 January 2009

A journal article published in 1876 has supported a researcher's suggestion that a decades-old arthritis drug could be a cheap  alternative in the treatment of diabetes, the Wall Street Journal  reports.

Salsalate, a non-steroidal, anti-inflammatory medication, that is  similar to aspirin and does not cause stomach bleeding, has been linked  to beneficial results in a modern setting for some time (Marketletter  February 11, 2008). Steven Sholeson, a researcher at Joslin Diabetes  Center in Massachusetts, USA, found confirmation of his theory that the  drug could be used as a cheap alternative in the treatment of type 2  diabetes in a German medical article from the 19th century.

According to the WSJ, the drug blocks a chemical pathway that may  provide the link between inflammation and diabetes that has long been  sought by researchers. The drug significantly lowered spikes in blood  sugar in a set of small trials in around 30 diabetics, with results from  a larger study forthcoming.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight